Add BrightSurf on Google Email

Study finds fewer breakthrough COVID-19 infections, lower risk of hospitalization in those who received Moderna vaccine compared to Pfizer–BioNTech

A new study published in the Journal of the American Medical Association finds that those who received the Moderna COVID-19 mRNA vaccine have a lower risk of experiencing 'breakthrough' COVID-19 cases compared to recipients of the Pfizer-BioNTech mRNA vaccine. The study also found that Moderna recipients were less likely to be hospital...

SourceCase Western Reserve University·JournalJournal of the American Medical Association·DateJan 20, 2022

Vaccine used in much of the world no match for Omicron variant

A new study by Yale researchers found that the Sinovac vaccine, widely used in 48 countries, offers little protection against the Omicron variant. Booster shots are necessary to combat the dominant circulating virus, which has shown to produce no neutralizing antibodies among those who received two doses of the Sinovac vaccine.

SourceYale University·JournalNature Medicine·DateJan 20, 2022

Why don’t people with COVID-19 symptoms get tested?

A new study of over 4 million adults in the UK found that people with COVID-19 symptoms are less likely to get tested due to barriers such as mild symptoms, poor knowledge of nearby testing sites, and certain demographic factors. The study suggests that targeted messaging and improved education are needed to increase test uptake.

SourcePLOS·JournalPLOS Global Public Health·TypeSurvey·DateJan 19, 2022

First study to detect Delta variant of SARS-CoV-2 in maternal bloodstream and placenta in cases of stillbirth and pregnancy complications

Researchers have detected the Delta variant of SARS-CoV-2 in the blood and placentas of women who experienced stillbirths and serious pregnancy complications. The study found that the virus was widely disseminated, causing severe inflammation of the placenta and leading to stillbirths.

SourceMassachusetts General Hospital·JournalThe Journal of Infectious Diseases·TypeObservational study·DateJan 13, 2022

What we do and don’t know about the many ways COVID-19 can impact pregnant women and their babies

The COVID-19 pandemic poses significant risks to pregnant women and their newborns, particularly due to viral-induced inflammation in the placenta. Studies have linked SARS-CoV-2 infection to adverse pregnancy outcomes, including stillbirth and severe neonatal illness, which may vary with specific circulating variants.

SourceChildren's National Hospital·JournalThe Journal of Infectious Diseases·DateJan 13, 2022

Unique Irish study sheds new light on long-term SARS-CoV-2 vaccine responses in older nursing home residents

A unique Irish study found that previous COVID-19 infection and age are associated with lower antibody levels six months after vaccination. The research highlights the importance of boosting vaccinations for vulnerable populations like nursing home residents.

SourceTrinity College Dublin·JournalJournal of the American Medical Directors Association·TypeExperimental study·DateJan 11, 2022

Using a different language can reduce vaccine hesitancy

A new study found that providing health information in a foreign language can reduce vaccine hesitancy. In a study conducted in Hong Kong, participants who received the same information in Cantonese showed lower willingness to get vaccinated compared to those who received it in English. The researchers suggest that language choice shou...

SourceUniversity of Exeter·JournalScientific Reports·TypeSurvey·DateJan 10, 2022

New: COVAX results

A registry study found that people with inflammatory RMDs, such as rheumatoid arthritis and psoriatic arthritis, tolerate their COVID vaccine well, with short-lived reactions being the most common side effect. The majority of participants were able to continue on their normal medication with no changes.

SourceEuropean Alliance of Associations for Rheumatology (EULAR)·JournalAnnals of the Rheumatic Diseases·DateJan 7, 2022

The Lancet: Phase 3 trial reports one dose of Ad5-nCoV COVID-19 vaccine is safe and effective, including against severe disease

A phase 3 trial has shown that one dose of the Ad5-nCoV COVID-19 vaccine is highly effective against severe disease, with an efficacy rate of 91.7% at 28 days post-vaccination. The vaccine has also been found to be safe, with no serious vaccine-related adverse events or deaths reported among trial participants.

SourceThe Lancet·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateDec 23, 2021

The role of trust and knowledge in overcoming vaccination hesitancy

A study published in PNAS found that trust and knowledge about vaccination are stronger predictors of vaccination than Covid-specific factors. Background beliefs and behavior regarding vaccination in general were more than twice as predictive of the change in vaccination as beliefs about the pandemic itself.

SourceAnnenberg Public Policy Center of the University of Pennsylvania·JournalProceedings of the National Academy of Sciences·TypeSurvey·DateDec 22, 2021

Covid-19 infections in nursing homes: Simulation model for optimal prevention and vaccination strategies

Austrian researchers developed a detailed epidemiological model to study the spread of coronavirus in nursing homes. The agent-based simulation tool helps balance safety and quality of life, considering vaccination rates and testing accuracy. With a high vaccination rate, major outbreaks are no longer expected.

SourceGraz University of Technology·JournalJournal of The Royal Society Interface·TypeComputational simulation/modeling·DateDec 22, 2021

COVID-19–vaccinated kidney transplant recipients are especially vulnerable to emerging SARS-CoV-2 variants

New research reveals that COVID-19 vaccinated kidney transplant recipients have impaired antibody responses against emerging SARS-CoV-2 variants, including B.1.351 and B.1.617.2. The study found that these patients require additional vaccinations to maintain high levels of neutralizing antibodies.

SourceAmerican Society of Nephrology·JournalClinical Journal of the American Society of Nephrology·DateDec 22, 2021

Gains in HPV vaccination coverage after interventions sustainable for several years

A new study found that multi-level interventions promoting staff training and early HPV vaccination starting at age 11 can sustain on-time vaccinations over several years. These findings suggest that targeted public health investments can improve vaccination rates, saving lives from HPV-related cancers.

SourceBoston University School of Medicine·JournalJournal of Lower Genital Tract Disease·TypeData/statistical analysis·DateDec 20, 2021